Icahn Enterprises is continuing its pursuit of Clorox, despite the company's rejection of last month's takeover bid.
Clorox has turned down an acquisition proposal from Icahn Enterprises valued at $76.50 per share, the company's board of directors announced Monday.
Clorox on Friday confirmed it has received an unsolicited conditional proposal from Icahn Enterprises to acquire the company for $76.50 per share, subject to due diligence, financing and other conditions.
Billionaire investor Carl Icahn is trying to kick Genzyme CEO Henri Termeer off the company’s...
Biogen Idec appointed a nominee of billionaire investor Carl Icahn to its board Monday, the...
It isn’t often that one of America’s premier retail companies finds itself the subject of...